A GlobalCures drug candidate may be added onto a currently accepted regimen.  In this case, a partnership with the pharmaceutical company manufacturing the currently used drug will be considered.  A fledgling biotech company may not have the funds to build biomarkers into its Phase I trial that would make the trial more informative – i.e. provide what is referred to in the industry as a “proof-of-concept” study.   Is the intended target in the tumor tissue being affected by the therapy?   GlobalCures might partner with such a company to fund such studies.  Another example: there are not enough patients being enrolled in a trial to provide statistical power to evaluate a particular endpoint.  GlobalCures might provide resources to fill that need.  In exchange for providing such resources, GlobalCures will expect to derive some revenue from the drug company if the drug is approved.